Gregor Novak

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Patients With Inflammatory Bowel Disease

Prognostic Factors

Rheumatoid Arthritis Patients

Monoclonal Antibody

Top Venues

Medicina (Kaunas, Lithuania)

This page only lists publications with an associated author ORCID identifier.

Publications

Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar, Gregor Novak
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina (Kaunas, Lithuania) 60 (2) (2024)
Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar, Gregor Novak
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina (Kaunas, Lithuania) 60 (2) (2024)
Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar, Gregor Novak
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina (Kaunas, Lithuania) 60 (2) (2024)
Jurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, Nejc Sever, Matic Koželj, Nataša Smrekar, Gregor Novak, Borut Štabuc, Erwin Dreesen, Debby Thomas, Tomaž Vovk, Barbara Ostanek, David Drobne, Iztok Grabnar
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics 13 (10) (2021)